Literature DB >> 1606787

Uses and limitations of positron emission tomography in clinical pharmacokinetics/dynamics (Part II).

L L Ponto1, J A Ponto.   

Abstract

Positron emission tomography (PET) involves imaging the biodistribution and tissue localisation of small amounts of radiolabelled biomolecules or drugs. In Part I of this article, which appeared in the previous issue of the Journal, the applications of pharmacokinetics in PET were discussed in order to derive quantitative measures of physiological function. Part II examines the use of PET imaging as a tool to study the pharmacokinetics and pharmacodynamics of specific drugs.

Mesh：

Substances：

Year:  1992        PMID： 1606787     DOI： 10.2165/00003088-199222040-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


  128 in total

1.  Maps of receptor binding parameters in the human brain--a kinetic analysis of PET measurements.

Authors:  G Blomqvist; S Pauli; L Farde; L Eriksson; A Persson; C Halldin
Journal:  Eur J Nucl Med       Date:  1990

2.  In reply: elevated d2 dopamine receptors in drug-naive schizophrenics.

Authors:  D F Wong; A Gjedde; H M Wagner; R F Dannals; J M Links; L E Tune; G D Pearlson
Journal:  Science       Date:  1988-02-12       Impact factor: 47.728

3.  Analysis of three- and four-compartment models for in vivo radioligand-neuroreceptor interaction.

Authors:  B R Zeeberg; H N Wagner
Journal:  Bull Math Biol       Date:  1987       Impact factor: 1.758

4.  Measurement of blood-brain hexose transport with dynamic PET: comparison of [18F]2-fluoro-2-deoxyglucose and [11C]O-methylglucose.

Authors:  K Herholz; K Wienhard; U Pietrzyk; G Pawlik; W D Heiss
Journal:  J Cereb Blood Flow Metab       Date:  1989-02       Impact factor: 6.200

5.  Nonoxidative glucose consumption during focal physiologic neural activity.

Authors:  P T Fox; M E Raichle; M A Mintun; C Dence
Journal:  Science       Date:  1988-07-22       Impact factor: 47.728

6.  Positron tomography. A new method for in vivo brain studies of benzodiazepine, in animal and in man.

Authors:  M Mazière; J M Godot; G Berger; J C Baron; D Comar; C Cepeda; C Menini; R Naquet
Journal:  Adv Biochem Psychopharmacol       Date:  1981

7.  Kinetics and displacement of [11C]RO 15-1788, a benzodiazepine antagonist, studied in human brain in vivo by positron tomography.

Authors:  Y Samson; P Hantraye; J C Baron; F Soussaline; D Comar; M Mazière
Journal:  Eur J Pharmacol       Date:  1985-04-02       Impact factor: 4.432

8.  Slowly progressive aphasia: three cases with language, memory, CT and PET data.

Authors:  D Kempler; E J Metter; W H Riege; C A Jackson; D F Benson; W R Hanson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-11       Impact factor: 10.154

9.  Noninvasive assessment of canine myocardial oxidative metabolism with carbon-11 acetate and positron emission tomography.

Authors:  M A Brown; D W Myears; S R Bergmann
Journal:  J Am Coll Cardiol       Date:  1988-10       Impact factor: 24.094

10.  Synthesis of ethyl 8-fluoro-5,6-dihydro-5-[11C]methyl-6-oxo-4H-imidazo [1,5-a] [1,4]benzodiazepine-3-carboxylate (RO 15.1788-11C): a specific radioligand for the in vivo study of central benzodiazepine receptors by positron emission tomography.

Authors:  M Maziere; P Hantraye; C Prenant; J Sastre; D Comar
Journal:  Int J Appl Radiat Isot       Date:  1984-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.